---
title: "Suprefort"
canonical_url: https://peptidelibrary.app/library/suprefort
description: "Peptide preparation derived from pancreatic tissue and marketed as a pancreatic bioregulator in the Khavinson tradition. Not FDA-approved for any indication. No study of Suprefort itself is indexed in PubMed; the studies cited here are class-level work on short peptide bioregulators."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Suprefort

Suprefort (also called Pancreas bioregulator) is a khavinson bioregulator. Suprefort is a peptide preparation derived from pancreatic tissue and marketed in the Khavinson tradition as a pancreatic bioregulator.

Peptide preparation derived from pancreatic tissue and marketed as a pancreatic bioregulator in the Khavinson tradition. Not FDA-approved for any indication. No study of Suprefort itself is indexed in PubMed; the studies cited here are class-level work on short peptide bioregulators.

Also known as: Pancreas bioregulator.

Categories: Fat Loss, GLP-1/Metabolic, Experimental.

## Classification

- Type: Khavinson bioregulator / research
- Mechanism class: Short Peptide Bioregulator
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

Suprefort is a peptide preparation derived from pancreatic tissue and marketed in the Khavinson tradition as a pancreatic bioregulator. It is a complex of low-molecular-weight peptides rather than a single defined molecule, so no specific sequence, receptor or pathway can be attributed to it, and it is distinct in that respect from Pancragen, the synthetic tetrapeptide associated with the same tissue. The proposed mechanism is the series hypothesis of tissue-derived peptides influencing transcription in the corresponding tissue. No controlled human efficacy trials of this preparation have been published.

Targets: Hepatocytes (proposed).

Origin: Peptide preparation from pancreatic tissue (per its description).

## Properties

- Half-life: Not established (small tripeptide)

## Evidence

- Evidence level: Insufficient Evidence
- Highest documented: None documented
- Human trials: 0
- Controlled human trials: 0
- Preclinical sources: 0

No human dose is established for this compound.

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Prospects of using pancragen for correction of metabolic disorders in elderly people. Bull Exp Biol Med. 2011. 2011. Human study (early or uncontrolled). Population: Older adults: 30 healthy and 33 with type 2 diabetes. In the diabetes group, pancragen lowered fasting glucose and glucose during a glucose tolerance test, and reduced insulin and the insulin-resistance index. Research on a related compound, not this one. Limitations: Studied an analog, not Suprefort itself [Source](https://pubmed.ncbi.nlm.nih.gov/22448364/)

## Safety

Side effects: Not characterized.

Risks: Research-only.

Human safety basis: No controlled human safety data

Key limitations: No established human dosage.; No controlled human trial results in the reviewed sources.; Not approved by the FDA for any use..

## Regulatory status

Suprefort is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- Availability: Research-Only

## Frequently asked questions

### What is Suprefort?

Peptide preparation derived from pancreatic tissue and marketed as a pancreatic bioregulator in the Khavinson tradition. Not FDA-approved for any indication. No study of Suprefort itself is indexed in PubMed; the studies cited here are class-level work on short peptide bioregulators.

### How does Suprefort work?

Suprefort is a peptide preparation derived from pancreatic tissue and marketed in the Khavinson tradition as a pancreatic bioregulator. It is a complex of low-molecular-weight peptides rather than a single defined molecule, so no specific sequence, receptor or pathway can be attributed to it, and it is distinct in that respect from Pancragen, the synthetic tetrapeptide associated with the same tissue.

### Is Suprefort FDA approved?

No. Suprefort is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

### What is the half-life of Suprefort?

Reported half-life for Suprefort is Not established (small tripeptide). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### What peptides are similar to Suprefort?

Compounds most often compared with Suprefort include Bonomarlot, Bronchogen, Cardiogen and Cartalax. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [Class-level evidence — Khavinson VK. Peptides and Ageing. Neuro Endocrinol Lett, 2002](https://pubmed.ncbi.nlm.nih.gov/12374906/)
- [Class-level evidence — Tissue-specific effects of peptides. Bull Exp Biol Med, 2001](https://pubmed.ncbi.nlm.nih.gov/11713572/)
- [Class-level evidence — Peptide bioregulation of aging: results and prospects — Biogerontology, 2010](https://pubmed.ncbi.nlm.nih.gov/19830585/)
- [Class-level evidence — Mechanisms underlying geroprotective effects of peptides — Bull Exp Biol Med, 2002](https://pubmed.ncbi.nlm.nih.gov/12170291/)
- [Class-level evidence — Epigenetic mechanisms of peptide-driven regulation and neuroprotective protein FKBP1b — Mol Biol (Mosk), 2019](https://pubmed.ncbi.nlm.nih.gov/31099784/)
